Gilead Announces Emvistegrast 200 Mg Met Primary Endpoint In Phase 2 Swift Dose-Ranging Study; Demonstrated Significant Differences Across Multiple Secondary Measures Of Disease Activity Based On Nominal P-Values; Plans To Initiate Phase 3 Emvistegrast Monotherapy Study In 2027

Gilead Sciences announced that its drug Emvistegrast met its primary endpoint in a Phase 2 swift dose-ranging study, showing significant differences across multiple secondary measures of disease activity based on nominal p-values. The company plans to initiate a Phase 3 study for Emvistegrast as monotherapy in 2027.